Many recombinant protein programs face critical expression challenges long before manufacturing begins. Poor yield, solubility issues, secretion limitations, and uncertain scalability can consume valuable time and resources — making it difficult to know which candidates are truly worth advancing.
Join this webinar to discover how early expression screening and strain-engineering strategies can help identify manufacturing risks sooner, generate more actionable data, and support confident go/no-go decisions before significant development investments are made.
Using real-world examples including antibody fragments, VHHs, enzymes, peptides, and other challenging recombinant proteins, our experts will explore how microbial expression screening can provide insight into expression performance, downstream feasibility, and scale-up potential at an early stage.
You’ll also learn how the Pfenex Expression Technology® platform can complement traditional expression systems such as E. coli and CHO, helping teams uncover alternative development paths when conventional approaches fall short.
Whether you’re working to improve expression, accelerate process development, or reduce uncertainty before scale-up, this session will provide practical strategies for moving difficult molecules forward with greater confidence.
What You’ll Learn:
- Spot manufacturing and scale-up challenges earlier before they become costly development setbacks
- Use expression screening data to make more informed candidate and platform-selection decisions, reducing uncertainty in development programs
- Evaluate critical factors that influence manufacturability, including yield, solubility, secretion, product quality, and downstream processing feasibility
- Determine when alternative expression technologies may offer advantages over traditional E. coli or CHO workflows for complex and engineered proteins
- Build a more data-driven path to scale-up and process development, helping de-risk programs and prioritize the most promising candidates
Diane Retallack
Diane Retallack, PhD was a founding member of the team that established the Pfenex Expression Technology® platform, overseeing strain engineering, HTP screening, and upstream development. With over 25 years of experience in molecular biology, protein expression, and executive management, she has contributed to multiple therapeutic programs from product conception through commercialization. Diane completed her doctorate at the University of Michigan and post-doctoral work at the University of Wisconsin-Madison.